{"id":"NCT00897949","sponsor":"Organon and Co","briefTitle":"MK0462 in Treatment of Migraine With Recurrence (MK0462-022)","officialTitle":"A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1995-03","primaryCompletion":"1996-01","completion":"1996-07","firstPosted":"2009-05-12","resultsPosted":"2011-05-04","lastUpdate":"2022-02-03"},"enrollment":1473,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Headache"],"interventions":[{"type":"DRUG","name":"rizatriptan benzoate (MK0462)","otherNames":[]},{"type":"DRUG","name":"Comparator: placebo","otherNames":[]}],"arms":[{"label":"Rizatriptan 10 mg","type":"EXPERIMENTAL"},{"label":"Rizatriptan 5 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.\n\nThe long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.","primaryOutcome":{"measure":"Pain Relief at 2 Hours After the Initial Dose of Test Drug","timeFrame":"2 hours after initial dose of test drug","effectByArm":[{"arm":"Rizatriptan 5 mg","deltaMin":285,"sd":null},{"arm":"Rizatriptan 10 mg","deltaMin":322,"sd":null},{"arm":"Placebo","deltaMin":106,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19222588","19210513","9595867","11284464"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":456},"commonTop":["Dizziness","Somnolence","Nausea","Asthenia/Fatigue","Paresthesia"]}}